[425] CureVac N.V. Business Combination Communication
BioNTech SE is pursuing the acquisition of CureVac N.V. via a commenced exchange offer for all outstanding CureVac shares. To facilitate the share-for-ADS exchange, BioNTech has filed a Form F-4 registration statement (including an Exchange Offer Prospectus) and a Schedule TO, while CureVac has filed a Schedule 14D-9. The F-4 has not yet been declared effective by the SEC.
The transaction remains subject to customary conditions, including tender levels and required regulatory approvals, and the parties cite risks such as competing proposals, litigation costs, and potential delays. In Europe, an EU Prospectus has been approved by BaFin for use in Austria, Germany, France, Italy, the Netherlands and Spain, and a UK exemption document has been published. Investors can access the SEC and regional offering documents free of charge through company websites and the SEC’s database.
BioNTech SE sta perseguendo l'acquisizione di CureVac N.V. tramite una offerta pubblica di scambio avviata per tutte le azioni CureVac in circolazione. Per facilitare lo scambio azione-ADS, BioNTech ha presentato una dichiarazione di registrazione Form F-4 (incluso un Prospetto dell'Offerta di Scambio) e un Schedule TO, mentre CureVac ha presentato un Schedule 14D-9. L'F-4 non è ancora stato dichiarato efficace dalla SEC.
La transazione resta soggetta a condizioni tipiche, comprese le soglie di offerta e le approvazioni regolamentari necessarie, e le parti citano rischi quali proposte concorrenti, costi legali e potenziali ritardi. In Europa, un EU Prospectus è stato approvato dalla BaFin per l'uso in Austria, Germania, Francia, Italia, Paesi Bassi e Spagna, e è stato pubblicato un documento di esenzione per il Regno Unito. Gli investitori possono accedere gratuitamente ai documenti SEC e regionali sull'offerta tramite i siti delle società e la banca dati della SEC.
BioNTech SE está persiguiendo la adquisición de CureVac N.V. mediante una oferta de intercambio iniciada para todas las acciones en circulación de CureVac. Para facilitar el intercambio de acciones por ADS, BioNTech ha presentado una declaración de registro Form F-4 (incluido un Prospecto de la Oferta de Intercambio) y un Schedule TO, mientras que CureVac ha presentado un Schedule 14D-9. El F-4 aún no ha sido declarado eficaz por la SEC.
La operación permanece sujeta a condiciones habituales, incluidas las tasas de tender y las aprobaciones regulatorias requeridas, y las partes señalan riesgos como propuestas competidoras, costos de litigio y posibles retrasos. En Europa, un EU Prospectus ha sido aprobado por BaFin para su uso en Austria, Alemania, Francia, Italia, Países Bajos y España, y se ha publicado un documento de exención para el Reino Unido. Los inversores pueden acceder gratuitamente a los documentos de la SEC y de oferta regional a través de los sitios web de las empresas y la base de datos de la SEC.
BioNTech SE는 모든 CureVac 주식을 대상으로 시작된 교환 제안을 통해 CureVac N.V.의 인수를 추진하고 있습니다. 주식-ADS 교환을 촉진하기 위해 BioNTech는 Form F-4 등록서류(교환제안 공고 포함)와 Schedule TO를 제출했고, CureVac는 Schedule 14D-9를 제출했습니다. F-4는 아직 SEC의 효력이 선언되지 않았습니다.
거래는 일반적인 조건, 예를 들어 인수 응찰 수준 및 필요한 규제 승인을 포함하여 여전히 조건부이며, 양측은 경쟁 제안, 소송 비용, 잠재적 지연 등의 위험을 지적합니다. 유럽에서 EU Prospectus가 BaFin에 의해 오스트리아, 독일, 프랑스, 이탈리아, 네덜란드, 스페인에서 사용하도록 승인되었고, UK 면제 문서가 게시되었습니다. 투자자들은 회사 웹사이트와 SEC 데이터베이스를 통해 SEC 및 지역 제안 문서를 무료로 열람할 수 있습니다.
BioNTech SE poursuit l'acquisition de CureVac N.V. par le biais d'une offre d'échange lancée pour toutes les actions CureVac en circulation. Pour faciliter l'échange actions-ADS, BioNTech a déposé une déclaration d'enregistrement Form F-4 (y compris un prospectus de l'offre d'échange) et un Schedule TO, tandis que CureVac a déposé un Schedule 14D-9. Le F-4 n'a pas encore été déclaré effectif par la SEC.
La transaction demeure sous conditions habituelles, y compris les niveaux d'acceptation et les approbations réglementaires requises, et les parties évoquent des risques tels que des propositions concurrentes, des coûts de litige et d'éventuels retards. En Europe, un EU Prospectus a été approuvé par BaFin pour une utilisation en Autriche, Allemagne, France, Italie, Pays-Bas et Espagne, et un document d'exemption pour le Royaume-Uni a été publié. Les investisseurs peuvent accéder gratuitement aux documents SEC et régionaux sur l'offre via les sites des sociétés et la base de données de la SEC.
BioNTech SE strebt den Erwerb von CureVac N.V. durch ein bereits eingeleitetes Austauschangebot für alle bestehenden CureVac-Aktien an. Um den Anteil-Aktien-zu-ADS-Austausch zu ermöglichen, hat BioNTech eine Form F-4-Registrierungserklärung (einschließlich eines Exchange Offer Prospectus) und einen Schedule TO eingereicht, während CureVac eine Schedule 14D-9 eingereicht hat. Das F-4 ist von der SEC noch nicht als wirksam erklärt worden.
Die Transaktion bleibt unter Vorbehalt üblicher Bedingungen, einschließlich der Tender-Niveaus und erforderlicher behördlicher Genehmigungen, und die Parteien nennen Risiken wie konkurrierende Angebote, Rechtsstreitkosten und potenzielle Verzögerungen. In Europa wurde ein EU Prospectus von BaFin zur Verwendung in Österreich, Deutschland, Frankreich, Italien, den Niederlanden und Spanien genehmigt, und ein britisches Exemption-Dokument wurde veröffentlicht. Anleger können kostenlos auf die SEC- und regionalen Angebotsdokumente über die Webseiten der Unternehmen und die SEC-Datenbank zugreifen.
BioNTech SE تسعى لاستحواذ CureVac N.V. من خلال عرض تبادل بدأ لجميع أسهم CureVac القائمة. ولتسهيل تبادل الأسهم مقابل ADS، قدمت BioNTech بيان تسجيل Form F-4 (بما في ذلك نشرة عرض التبادل) وSchedule TO، بينما قدمت CureVac Schedule 14D-9. لم يتم بعد إعلان فعالية F-4 من قِبل SEC.
تبقى الصفقة خاضعة للشروط المعتادة، بما في ذلك مستويات التسليم والموافقات التنظيمية المطلوبة، وتذكر الأطراف مخاطر مثل وجود عروض منافسة وتكاليف التقاضي وتأخيرات محتملة. في أوروبا، تمت الموافقة على EU Prospectus من قبل BaFin للاستخدام في النمسا وألمانيا وفرنسا وإيطاليا وهولندا وإسبانيا، وتم نشر وثيقة استثناء للمملكة المتحدة. يمكن للمستثمرين الوصول إلى وثائق SEC والوثائق المحلية الخاصة بالعرض مجاناً عبر مواقع الشركات وقاعدة بيانات SEC.
BioNTech SE 正在通过启动的交易所要约推进对 CureVac N.V. 的收购，覆盖 CureVac 所有已发行的股份。为促进股份与 ADS 的交换，BioNTech 已提交一份 Form F-4 登记声明（包括交易所要约招股说明书）和一份 Schedule TO，而 CureVac 已提交一份 Schedule 14D-9。F-4 尚未被美国证券交易委员会（SEC）宣布生效。
该交易仍受通常条件约束，包括要约接受水平和所需的监管批准，双方还指出存在诸如竞争性提案、诉讼成本和潜在延迟等风险。在欧洲，BaFin 已批准用于奥地利、德国、法国、意大利、荷兰和西班牙的 EU Prospectus，并发布了英国豁免文件。投资者可通过公司网站和 SEC 数据库免费获取 SEC 及区域性要约文件。
- None.
- None.
Insights
Exchange offer launched; filings in place, effectiveness and tenders pending.
BioNTech has commenced an exchange offer to acquire all CureVac shares, registering BioNTech ADSs via a Form F-4. A Schedule TO and Schedule 14D-9 are on file, indicating the deal is procedurally advancing but still awaiting SEC effectiveness of the F-4 and fulfillment of offer conditions.
Completion depends on regulatory approvals, shareholder tenders, and the absence of superior proposals. The disclosure flags risks including potential litigation, transaction costs, and operational distraction, as well as macro factors like interest rates and geopolitical events.
In Europe, the EU Prospectus has BaFin approval for specified countries, and the UK has a published exemption document. Subsequent filings may provide the exchange ratio, acceptance levels, and timing milestones that determine closing.
BioNTech SE sta perseguendo l'acquisizione di CureVac N.V. tramite una offerta pubblica di scambio avviata per tutte le azioni CureVac in circolazione. Per facilitare lo scambio azione-ADS, BioNTech ha presentato una dichiarazione di registrazione Form F-4 (incluso un Prospetto dell'Offerta di Scambio) e un Schedule TO, mentre CureVac ha presentato un Schedule 14D-9. L'F-4 non è ancora stato dichiarato efficace dalla SEC.
La transazione resta soggetta a condizioni tipiche, comprese le soglie di offerta e le approvazioni regolamentari necessarie, e le parti citano rischi quali proposte concorrenti, costi legali e potenziali ritardi. In Europa, un EU Prospectus è stato approvato dalla BaFin per l'uso in Austria, Germania, Francia, Italia, Paesi Bassi e Spagna, e è stato pubblicato un documento di esenzione per il Regno Unito. Gli investitori possono accedere gratuitamente ai documenti SEC e regionali sull'offerta tramite i siti delle società e la banca dati della SEC.
BioNTech SE está persiguiendo la adquisición de CureVac N.V. mediante una oferta de intercambio iniciada para todas las acciones en circulación de CureVac. Para facilitar el intercambio de acciones por ADS, BioNTech ha presentado una declaración de registro Form F-4 (incluido un Prospecto de la Oferta de Intercambio) y un Schedule TO, mientras que CureVac ha presentado un Schedule 14D-9. El F-4 aún no ha sido declarado eficaz por la SEC.
La operación permanece sujeta a condiciones habituales, incluidas las tasas de tender y las aprobaciones regulatorias requeridas, y las partes señalan riesgos como propuestas competidoras, costos de litigio y posibles retrasos. En Europa, un EU Prospectus ha sido aprobado por BaFin para su uso en Austria, Alemania, Francia, Italia, Países Bajos y España, y se ha publicado un documento de exención para el Reino Unido. Los inversores pueden acceder gratuitamente a los documentos de la SEC y de oferta regional a través de los sitios web de las empresas y la base de datos de la SEC.
BioNTech SE는 모든 CureVac 주식을 대상으로 시작된 교환 제안을 통해 CureVac N.V.의 인수를 추진하고 있습니다. 주식-ADS 교환을 촉진하기 위해 BioNTech는 Form F-4 등록서류(교환제안 공고 포함)와 Schedule TO를 제출했고, CureVac는 Schedule 14D-9를 제출했습니다. F-4는 아직 SEC의 효력이 선언되지 않았습니다.
거래는 일반적인 조건, 예를 들어 인수 응찰 수준 및 필요한 규제 승인을 포함하여 여전히 조건부이며, 양측은 경쟁 제안, 소송 비용, 잠재적 지연 등의 위험을 지적합니다. 유럽에서 EU Prospectus가 BaFin에 의해 오스트리아, 독일, 프랑스, 이탈리아, 네덜란드, 스페인에서 사용하도록 승인되었고, UK 면제 문서가 게시되었습니다. 투자자들은 회사 웹사이트와 SEC 데이터베이스를 통해 SEC 및 지역 제안 문서를 무료로 열람할 수 있습니다.
BioNTech SE poursuit l'acquisition de CureVac N.V. par le biais d'une offre d'échange lancée pour toutes les actions CureVac en circulation. Pour faciliter l'échange actions-ADS, BioNTech a déposé une déclaration d'enregistrement Form F-4 (y compris un prospectus de l'offre d'échange) et un Schedule TO, tandis que CureVac a déposé un Schedule 14D-9. Le F-4 n'a pas encore été déclaré effectif par la SEC.
La transaction demeure sous conditions habituelles, y compris les niveaux d'acceptation et les approbations réglementaires requises, et les parties évoquent des risques tels que des propositions concurrentes, des coûts de litige et d'éventuels retards. En Europe, un EU Prospectus a été approuvé par BaFin pour une utilisation en Autriche, Allemagne, France, Italie, Pays-Bas et Espagne, et un document d'exemption pour le Royaume-Uni a été publié. Les investisseurs peuvent accéder gratuitement aux documents SEC et régionaux sur l'offre via les sites des sociétés et la base de données de la SEC.
BioNTech SE strebt den Erwerb von CureVac N.V. durch ein bereits eingeleitetes Austauschangebot für alle bestehenden CureVac-Aktien an. Um den Anteil-Aktien-zu-ADS-Austausch zu ermöglichen, hat BioNTech eine Form F-4-Registrierungserklärung (einschließlich eines Exchange Offer Prospectus) und einen Schedule TO eingereicht, während CureVac eine Schedule 14D-9 eingereicht hat. Das F-4 ist von der SEC noch nicht als wirksam erklärt worden.
Die Transaktion bleibt unter Vorbehalt üblicher Bedingungen, einschließlich der Tender-Niveaus und erforderlicher behördlicher Genehmigungen, und die Parteien nennen Risiken wie konkurrierende Angebote, Rechtsstreitkosten und potenzielle Verzögerungen. In Europa wurde ein EU Prospectus von BaFin zur Verwendung in Österreich, Deutschland, Frankreich, Italien, den Niederlanden und Spanien genehmigt, und ein britisches Exemption-Dokument wurde veröffentlicht. Anleger können kostenlos auf die SEC- und regionalen Angebotsdokumente über die Webseiten der Unternehmen und die SEC-Datenbank zugreifen.
Filed by BioNTech SE
(Commission File No. 001-39081)
pursuant to Rule 425 under the
Securities Act of 1933, as amended.
Subject Company: CureVac N.V.
(Commission File No.: 001-39446)
Registration No.: 333-289468
The following communication is being filed in connection with the proposed acquisition of CureVac N.V. by BioNTech SE.
Cautionary Statement Regarding Forward-Looking Statements
This document includes “forward-looking statements.” Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “look forward,” “investigational,” “pipeline,” “to acquire,” “development,” “to include,” “commitment,” or similar terms. Such forward-looking statements include, but are not limited to, statements relating to the ability of BioNTech SE to complete its previously announced exchange offer (the “Offer”) to acquire all of the outstanding shares of CureVac N.V. (“CureVac”) and other transactions contemplated by the Purchase Agreement, dated as of June 12, 2025, by and between BioNTech and CureVac (the “Purchase Agreement”) (including the parties’ ability to satisfy the conditions to the consummation of the Offer contemplated thereby and the other conditions set forth in the Purchase Agreement), the expected timetable for completing the transactions, the benefits sought to be achieved in the proposed transactions, the potential and capacity of BioNTech following the transaction, and the potential effects of the proposed transactions on BioNTech and CureVac. Many of these risks and uncertainties are beyond the control of BioNTech or CureVac. Investors are cautioned that any such forward-looking statements are based on BioNTech’s or CureVac’s current beliefs and expectations regarding future events and are not guarantees of future performance and involve risks and uncertainties. There can be no guarantees that the conditions to the closing of the transactions will be satisfied on the expected timetable or at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.
Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the Offer and the subsequent corporate reorganization of CureVac; uncertainties as to how many of CureVac’s shareholders will tender their shares in the Offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the Offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived; the possibility of a termination of the Purchase Agreement; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the announcement and pendency of the transactions on BioNTech’s and/or CureVac’s business, including their relationships with employees, business partners or governmental entities; the risk that the Offer or the other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated; the risk that litigation in connection with the Offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the Offer, the other transactions contemplated by the Purchase Agreement or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and the ongoing Russia-Ukraine and Middle East conflicts; the impact of regulatory developments and changes in the United States, Europe and countries outside of Europe, including with respect to tax matters; the impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere; the particular prescribing preferences of physicians and patients; competition from other products; challenges and uncertainties inherent in new product development; ability to obtain or maintain proprietary intellectual property protection; safety, quality, data integrity or manufacturing issues; and potential or actual data security and data privacy breaches.
Neither BioNTech nor CureVac undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in BioNTech’s and CureVac’s respective Annual Report on Form 20-F for the year ended December 31, 2024, in each case as amended by any subsequent filings made with the SEC, available on the SEC’s website at www.sec.gov.
Notice to Investors and Security Holders
This document is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the Offer, BioNTech has filed a Registration Statement on Form F-4 and amendments thereto (as so amended, the “Registration Statement”) with the SEC, including an offer to exchange/prospectus (the “Exchange Offer Prospectus”), to register under the Securities Act of 1933, as amended, the issuance of BioNTech ADSs. Such Registration Statement has not yet been declared effective by the SEC. In addition, BioNTech has filed with the SEC a tender offer statement on Schedule TO (the “Schedule TO”), which includes, as exhibits, the Exchange Offer Prospectus, a form of letter of transmittal, and other customary ancillary documents and CureVac has filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the “Schedule 14D-9”). The Offer has commenced. The solicitation and offer to exchange CureVac Shares is being made only pursuant to the Schedule TO and related Exchange Offer Prospectus or the EU Prospectus or the UK exemption document (each as referred to below). This material is not a substitute for the Exchange Offer Prospectus, the Schedule TO, the Schedule 14D-9, the Registration Statement or for any other document that BioNTech or CureVac has filed or may file with the SEC and has sent or will send to CureVac’s shareholders in connection with the proposed transactions.
BEFORE MAKING ANY INVESTMENT DECISION OR DECISION WITH RESPECT TO THE OFFER, WE URGE INVESTORS OF CUREVAC TO READ THE REGISTRATION STATEMENT, EXCHANGE OFFER PROSPECTUS, SCHEDULE TO (INCLUDING THE EXCHANGE OFFER PROSPECTUS, RELATED LETTER OF TRANSMITTAL, AND OTHER OFFER DOCUMENTS) AND SCHEDULE 14D-9, THE EU PROSPECTUS (IF RELEVANT), THE UK EXEMPTION DOCUMENT (IF RELEVANT), AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND OTHER RELEVANT DOCUMENTS CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT BIONTECH, CUREVAC AND THE PROPOSED TRANSACTIONS THAT HOLDERS SHOULD CONSIDER.
Investors can obtain free copies of the Registration Statement, Exchange Offer Prospectus, Schedule TO and Schedule 14D-9, as each may be amended from time to time, and other relevant documents filed by BioNTech and CureVac with the SEC at http://www.sec.gov, the SEC’s website, or free of charge from BioNTech’s website (https://www.biontech.com) or by contacting BioNTech’s Investor Relations Department at Investors@biontech.de. These documents are also available free of charge from CureVac’s website (https://www.curevac.com) or by contacting CureVac’s Investor Relations Department at communications@curevac.com. All documents are also available from Georgeson, LLC, the information agent for the Offer, at +1 888 686-7195 (toll free), +1 732 353-1948 (collect) or Curevacoffer@georgeson.com.
EEA
With respect to the public offering of BioNTech ADSs to the shareholders of CureVac in Austria, Germany, France, Italy, the Netherlands and Spain, this document is an advertisement for the purposes of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”). With respect to the public offering of BioNTech ADSs to shareholders of CureVac in Switzerland, this document constitutes advertising in accordance with article 68 Swiss Financial Services Act of 15 June 2018 (the “FinSA”). This document does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the securities prospectus (the “EU Prospectus”) which is be available free of charge, together with the relevant translation(s) of the summary and any supplements thereto, if any, from BioNTech’s website (https://investors.biontech.de/eea-switzerland-disclaimer). The EU Prospectus has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and is, therefore, considered approved in Switzerland by the review body of SIX Exchange Regulation Ltd. pursuant to the FinSA. The approval of the securities prospectus by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) should not be understood as an endorsement of the investment in any BioNTech ADSs or shares in BioNTech.
In relation to each state which is a party to the agreement relating to the European Economic Area (a “Relevant Member State”) the offer to exchange all of the CureVac shares for BioNTech ADSs contemplated by the EU Prospectus is not made in that Relevant Member State, except as set out below. No BioNTech ADSs have been offered or will be offered to the public in a Relevant Member State other than in Austria, Germany, France, Italy, the Netherlands and Spain, in each case based on the EU Prospectus, except that BioNTech ADSs may be offered to the public in a Relevant Member State at any time under the following exemptions under the Prospectus Regulation: (i) to any qualified investor as defined in Article 2 lit. (e) of the Prospectus Regulation, (ii) to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 lit. (e) the Prospectus Regulation), or (iii) in any other circumstances falling within Article 1 para. 4 of the Prospectus Regulation, provided that no such offer (as set forth in clauses (i) to (ii)) of BioNTech ADSs will result in a requirement for the publication by BioNTech of a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.
In relation to Switzerland, the offer of BioNTech ADSs to the public in Switzerland is based on the EU Prospectus, which is considered to be approved by and has been registered and filed with the review body of SIX Exchange Regulation Ltd., or otherwise under the exemptions specified in the FinSA and the Swiss Financial Services Ordinance of 6 November 2019.
Investors in Austria, Germany, France, Italy, the Netherlands and Spain as well as investors in Switzerland should acquire BioNTech ADSs solely on the basis of the EU Prospectus (including the documents incorporated by reference therein and any supplements thereto, if any) relating to the BioNTech ADSs and should read the EU Prospectus (including any documents incorporated by reference therein and any supplements thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment.
UK
With respect to the public offering of BioNTech ADSs to CureVac shareholders in the United Kingdom (the “UK”), BioNTech has published a UK exemption document for the purposes of the prospectus regulation EU 2017/1129 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. This document does not constitute an offer to purchase any BioNTech ADSs or shares in BioNTech and does not replace the UK exemption document which is available free of charge from BioNTech’s website (https://investors.biontech.de/uk-disclaimer).
Investors in the UK should acquire BioNTech ADSs solely on the basis of the UK exemption document (including the documents incorporated by reference therein and any updates thereto, if any) relating to the BioNTech ADSs and should read the UK exemption document (including the documents incorporated by reference therein and any updates thereto, if any) before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the BioNTech ADSs. Investment in BioNTech ADSs entails numerous risks, including a total loss of the initial investment.
FAQ
What transaction has BioNTech proposed for CureVac (CVAC)?
Which SEC documents related to CVAC’s deal are available?
Has the exchange offer for CureVac begun and what remains outstanding?
Where can CureVac (CVAC) shareholders access the offer documents?
What European and UK documents support the BioNTech–CureVac offer?
What key risks to closing does the communication highlight?
What agreement governs the transaction between BioNTech and CureVac?
